Germline-somatic interactions as drivers and therapeutic targets in bladder cancerBMBishoy Morris FaltasOEOlivier ElementoAmerican Cancer Society · 2026–2030RSG-25-1511719-01-ETActive
Targeting latency switch for the treatment of EBV-associated lymphomasIYIsabella Yingjia KongGGGiorgio Ga. InghiramiLGLisa Giulino RothAmerican Cancer Society · 2024–2026PF-23-1143526-01-IBCDEnding soon
Dyadic communication intervention to increase patient advance care planning.MJMegan Johnson ShenHGHolly G PrigersonPKPaul K MaciejewskiAmerican Cancer Society · 2018–2020 · via Memorial Sloan Kettering Cancer Center132386-PEP-18-052-01-PCSM1
Safeguarding T cell cytoskeletal integrity for improved cancer immunotherapyJRJuan R Cubillos-RuizDADeepika AwasthiAmerican Cancer Society · 2025–2027YACS-24-1331842-01-YACSActive
State opioid limits, formulary design, and intended and unintended consequences for people with cancerYBYuhua BaoRTRulla TamimiAmerican Cancer Society · 2023–2026RSGI-22-130-01-HOPSEnding soon
Defining Rac1-mediated bypass of senescence as a molecular vulnerability in pancreatic cancerRCRohit ChandwaniAmerican Cancer Society · 2025–2028RSG-24-1325001-01-MMActive
Role of Chromatin Remodeling Complexes in Clonal Evolution of Blood CancersDBDarko BarisicAmerican Cancer Society · 2026–2027CAT-26-1609195-01-CAT-W25Ending soon
Harnessing Innate Immunity for Next-Generation Immuno-Oncology TherapeuticsDADan Avi LandauSCSilvia Chiara FormentiAmerican Cancer Society · 2024–2026YACS-24-1331829-01-YACSEnding soon
Defining Evolutionary Trajectories Driving Prostate Cancer MetastasesDNDawid NowakLBLise BraultAmerican Cancer Society · 2021–2026RSG-21-057-01-SCMEnding soon
Lineage plasticity as a mechanism of therapy resistance in prostate cancerNBNicholas BradyDSDavid S. RickmanAmerican Cancer Society · 2021–2023PF-20-119-01-TBE
Uncovering the molecular mechanisms of LRRK2 regulation in the inflammatory responseKSKatherine SurridgeAmerican Cancer Society · 2026–2027PF-25-1516576-01-PFMBBEnding soon
Harnessing ecDNA amplification signals in plasma whole genome for cancer detectionQLQing LuoAmerican Cancer Society · 2026–2029PF-25-1505281-01-PFCDETActive
CA Amendment No. 1 for Denise Gelfand (Original Agreement WRG# 18760)HGHolly G PrigersonContractAmerican Cancer Society · 2018–2018CA 191712-01
Enhancing and Mobilizing Caregivers' Potential for Wellness & ResilienceHGHolly G PrigersonLLLindsay LiefPKPaul K MaciejewskiAmerican Cancer Society · 2017–2019ACS 17040601-01
FLOW - Flatiron Clinical Pipe™ for Optimized Workflow for Cancer Clinical TrialsJZJudy ZhongJCJim C. HuSTScott T. TagawaAmerican Cancer Society · 2026–2027CTTRIA-25-1497791-01-CTTRIAActive
Tumor Dormancy and Therapy Resistance in RSPO Fusion CRCLELukas Edward DowAmerican Cancer Society · 2018–2021RSG-17-202-01-TBG
Germline-somatic interactions as drivers and therapeutic targets in bladder cancerBMBishoy Morris FaltasAmerican Cancer Society · 2025–2025CAT-24-1413358-01-CATEnding soon
Improving cervical cancer patient treatment and outcomes with the development of a modernized, novel gynecologic brachytherapy deviceJKJeffrey KetterlingTBTracy B GrossmanAmerican Cancer Society · 2024–2025EDS-24-1333815-01-EDSRecently ended
The role of stromal androgen receptor (AR) in the plasticity to advanced prostate cancer (Postdoctoral Fellowship Application)FPFilippo PederzoliAmerican Cancer Society · 2025–2027PF-24-1318851-01-MMActive
Analysis of ACA Insurance Provisions: Smoking and Cancer Risk ImplicationsMFMichael F. PeskoAmerican Cancer Society · 2016–2017ACS 170918-2